IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Buys 14,712 Shares

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin acquired 14,712 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The shares were purchased at an average cost of $0.94 per share, with a total value of $13,829.28. Following the transaction, the insider directly owned 620,630 shares of the company’s stock, valued at $583,392.20. This trade represents a 2.43% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

IRIDEX Stock Up 2.2%

Shares of IRIDEX stock opened at $0.90 on Friday. The company has a market capitalization of $15.78 million, a price-to-earnings ratio of -4.49 and a beta of 0.67. IRIDEX Corporation has a 12-month low of $0.61 and a 12-month high of $1.65. The firm’s 50-day moving average price is $0.73 and its two-hundred day moving average price is $0.95.

IRIDEX (NASDAQ:IRIX) last issued its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The firm had revenue of $12.57 million for the quarter, compared to the consensus estimate of $13.59 million. On average, sell-side analysts expect that IRIDEX Corporation will post -0.12 earnings per share for the current year.

Hedge Funds Weigh In On IRIDEX

Institutional investors have recently added to or reduced their stakes in the stock. Weber Capital Management LLC ADV bought a new position in IRIDEX in the 2nd quarter valued at approximately $206,616. United Capital Financial Advisors LLC bought a new stake in shares of IRIDEX during the second quarter worth $41,000. Diversify Advisory Services LLC bought a new stake in shares of IRIDEX during the second quarter worth $30,000. Diversify Wealth Management LLC acquired a new position in shares of IRIDEX during the first quarter worth $35,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of IRIDEX during the second quarter worth $29,000. 20.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $3.00.

Trending Headlines about IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
• Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
• Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
• Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.